JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2015, 64(1):7-13 | DOI: 10.36290/csf.2015.002

Bioavailability and factors influencing its rate

Barbora Vraníková, Jan Gajdziok*
Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta, Ústav technologie léků, Brno

Bioavailability can be defined as the rate and range of active ingredient absorption, when it becomes available in the systemic circulation or at the desired site of drug action, respectively. Drug bioavailability after oral administration is affected by anumber of different factors, including physicochemical properties of the drug, physiological aspects, the type of dosage form, food intake, biorhythms, and intra- and interindividual variability of the human population. This article is the first from the series dealing with the bioavailability and methods leading to its improvement. The aim of the present paper is to provide an overview of aspects influencing the rate of bioavailability after oral administration of the active ingredient. Subsequentarticles will provide detailed descriptions of methods used for dug bioavailability improvement, which are here only summarized.

Keywords: bioavailability; drug solubility; poorly soluble drugs; factors influencing bioavailability

Received: January 21, 2015; Accepted: February 16, 2015; Published: January 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vraníková B, Gajdziok J. Bioavailability and factors influencing its rate. Čes. slov. farm. 2015;64(1-2):7-13. doi: 10.36290/csf.2015.002.
Download citation

References

  1. Kawabata Y., Wada K., Nakatani M., Yamada S., Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications. Int. J. Pharm. 2011; 420, 1-10. Go to original source... Go to PubMed...
  2. Rasenack N., Müller B. W. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm. Res. 2002; 19, 1894-1900. Go to original source... Go to PubMed...
  3. Keck C. M., Müller R. H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 2006; 62, 3-16. Go to original source... Go to PubMed...
  4. Vasconcelos T., Sarmento B., Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 2007; 12, 1068-1075. Go to original source... Go to PubMed...
  5. Gursoy R. N., Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomedicine and Pharmacotherapy. 2004; 58, 173-182. Go to original source... Go to PubMed...
  6. Vraníková B., Gajdziok J., Vetchý D., Kratochvíl B., Seilerová L. Systémy kapalina v pevné fázi jako moderní trend zvyšování biologické dostupnosti léčiva. Chem. Listy 2013; 107, 681-687.
  7. Lüllmann H., Mohr K., Wehling M. Farmakologie a toxikologie. 2. vydání Praha: Grada Publishing 2004.
  8. Lincová, D., Farghali, H. Základní a aplikovaná farmakologie. 2. vydání. Praha: Galén 2007.
  9. Allam A. N., El Gamal, S. S., Naggar V. F. Bioavailability: a pharmaceutical review. Int. J. Nov. Drug Deliv. Tech. 2001; 1, 80-96.
  10. van de Waterbeemd H., Testa B., Mannhold R., Kubinyi H., Folkers G. Drug Bioavailability: Estimation of solubility, Permeability, Absorption and Bioavailability. 2nd Edition. Weinheim: John Wiley & Sons 2009. Go to original source...
  11. Komárek P., Rabišková M. Technologie léků. 3. přepracované a doplněné vydání. Praha: Galén 2006.
  12. Lipinski C. A., Lombardo F., Dominy B. W., Feeney P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001; 46, 3-26. Go to original source... Go to PubMed...
  13. Okáčová L., Vetchý D., Franc A., Rabišková M., Kratochvíl B. Zvýšení biodostupnosti těžce rozpustných léčivých látek jejich modifikací. Chem. Listy 2010; 104, 21-26.
  14. Český lékopis 2009. 1. vydání. Praha: Grada Publishing 2009.
  15. Yazdanian M., Briggs K., Jankovsky C., Hawi A. The "high solubility" definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm. Res. 2004; 21, 293-299. Go to original source... Go to PubMed...
  16. Amidon G. L., Lennernäs H., Shah V. P., Crison J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995; 12, 413-420. Go to original source... Go to PubMed...
  17. Chavda H. V., Patel C. N., Anand I. S. Biopharmaceutics classification system. Syst. Rev. Pharm. 2010; 1: 62-69. Go to original source...
  18. van De Waterbeemd H., Smith D. A., Beaumont K., Walker D. K. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 2001; 44, 1313-1333. Go to original source... Go to PubMed...
  19. Dostálek M. Farmakokinetika. Praha: Grada Publishing 2006.
  20. Li X., Hu M. Oral bioavailability: basic principles, advanced concepts, and applivations. 1st edition. Weinheim: John Wiley & Sons 2011.
  21. Farsa O. Terapeutické monoklonální protilátky v léčbě a ve vývoji. Chem. Listy 2013; 107, 464-470.
  22. Kratochwil N. A., Huber W., Müller F., Kansy M., Gerber P. R. Predicting plasma protein binding of drugs: a new approach. Biochem. Pharmacol. 2002; 64, 1355-1374. Go to original source... Go to PubMed...
  23. Lüllmann, H., Mohr, K., Hein, Lutz. Barevný atlas farmakologie. 3. vyd. Praha: Grada Publishing 2007.
  24. Alhamami O. M. Delay in gastric emptying rate enhances bioavailability of sodium salicylates in rabbit. Arch. Pharm. Res. 2007; 30, 1144-1148. Go to original source... Go to PubMed...
  25. Mearrick P. T., Wade D. N., Birkett D. J., Morris J. Metoclopramide, gastric emptying and L-dopa absorption. Aust. N. Z. J. Med. 1974; 4, 144-148. Go to original source... Go to PubMed...
  26. Amir I., Anwar N., Baraona E., Lieber C. S. Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emtying. Life Sci. 1996; 58, 511-518. Go to original source... Go to PubMed...
  27. Dressman J. B., Berardi R. R., Dermentzoglou L. C., Russell T. L., Schmaltz S. P., Barnett J. L., Jarvenpaa K. M. Upper gastrointestinal (GI) pH young healthy men and women. Pharm. Res. 1990; 7, 756-761. Go to original source... Go to PubMed...
  28. Augustijns P., Brewster M. Solvent systems and their selection in pharmaceutics and biopharmaceutics. Berlin: Springer Science & Business Media 2007. Go to original source...
  29. Zhou D., Qiu Y. Oral Absorption and the Biopharmaceutics Classification System. Journal of validation technology 2009; 15, 62-72.
  30. Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan. Med. Bull. 1999; 46, 183-196.
  31. Dvořáčková K., Franc A., Kejdušová M. Směrování léčiv do tlustého střeva. Chem. Listy 2013; 107, 522-529.
  32. Kwan K. C. Oral bioavailability and first-pass effects. Drug Metab. Dispos. 1997; 25, 1329-1336.
  33. Levy G., Gumtow R. H., Rutowski J. M. The Effect of Dosage form upon the Gastrointestinal Absorption Rate of Salicylates. Can. Med. Assoc. J. 1961; 85, 414-419.
  34. Melander A. Influence of food on the bioavailability of drugs. Clin. Pharmacokinet. 1978; 3, 337-351. Go to original source... Go to PubMed...
  35. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126831.pdf. (12. 1. 2015).
  36. Moses D. K., Charles B. G., Ravenscroft P. J., Whyte I. M. Food reduces the oral bioavailability of propantheline bromide in healthy subjects. Br. J. Clin. Pharmacol. 1983; 16, 758-759. Go to original source... Go to PubMed...
  37. Lecaillon J. B., Godbillon J., Campestrini J., Naquira C., Miranda L., Pacheco R., Mull R., Poltera A. A. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br. J. Clin. Pharmacol. 1998; 45, 601-604. Go to original source... Go to PubMed...
  38. Lemmer B. Relevance for chronopharmacology in practical medicine. Semin. Perinatol. 2000; 24, 280-290. Go to original source... Go to PubMed...
  39. Griffett K., Burris T. P. The mammalian clock and chronopharmacology. Bioorg. Med. Chem. Lett. 2013; 23, 1929-1934. Go to original source... Go to PubMed...
  40. Ptáček R., Bartůněk P. a kol. Etické problémy medicíny na prahu 21. století. 1. vydání. Praha: Grada Publishing 2014.
  41. Kovarik J. M., Mueller E. A., van Bree J. B., Tetzloff W., Kutz K. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J. Pharm. Sci. 1994; 83, 444-446. Go to original source... Go to PubMed...
  42. Lebbe C., Beyeler C., Gerber N. J., Reichen J. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann. Rheum. Dis. 1994; 53, 475-477. Go to original source... Go to PubMed...
  43. Grahnén A., Hammarlund M., Lundqvist T. Implications of intraindividual variability in bioavailability studies of furosemide. Eur. J. Clin. Pharmacol. 1984; 27, 595-602. Go to original source... Go to PubMed...
  44. Kataria M. K., Bhandari A. Solubility and dissolution enhancement: technologies and research emerged. Journal of Biological and Scientific Opinion 2013; 1, 105-116. Go to original source...
  45. Kusumi S., Tomono S., Okuzawa S., Kaneko E., Ueda T., Sasaki K., Takahashi D., Toshima K. Total synthesis of vineomycin B2. J. Am. Chem. Soc. 2013; 135, 15909-15912. Go to original source... Go to PubMed...
  46. Vishweshwar P., McMahon J. A., Bis J. A., Zaworotko M. J. Pharmaceutical Co-Crystals. J. Pharm. Sci. 2006; 95, 499-516. Go to original source... Go to PubMed...
  47. Hetal T., Bindesh P., Sneha T. A review on techniques for oral bioavailability enhancement of drugs. International Journal of Pharmaceutical Sciences Review and Research 2010; 4, 203-223.
  48. Offermanns S., Rosenthal W. Encyclopedia of molecular pharmacology. 2nd edition. Berlin: Springer Science & Business Media 2008. Go to original source...
  49. Djokic S., Vajtner Z., Krnjevic H., Lopotar N., Kolacny-Babic L. Complexes and chelates of azithromycin with bivalent and/or trivalent metals and their use as antiulcer. 1990; US5498699A.
  50. Hancock B. C., Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 2000; 17, 397-404. Go to original source... Go to PubMed...
  51. Pudipeddi M., Serajuddin A. T. M. Trends in solubility of polymorphs. J. Pharm. Sci. 2005; 94, 929-939. Go to original source... Go to PubMed...
  52. Kaur J., Aggarwal G., Gurpreet S., Rana A. C. Improvement of drug solubility using solid dispersion. International Journal of Pharmacy and Pharmaceutical Sciences. 2012; 4, 47-53.
  53. Gowardhane A. P., Kadam N. V., Dutta S. Review on enhancement of solubilisation precess. Journal of Pharmacy and Phytotherapeutics 2013; 2, 28-38.
  54. Maheshwari M., Jahagirdar H., Paradkar A. Melt sonocrystallization of ibuprofen: Effect on crystal properties. European Journal of Pharmaceutical Sciences. 2005; 25, 41-48. Go to original source... Go to PubMed...
  55. Chuchvalec P., Novák J. P. Kritické veličiny látek a jejich predikce. Chem. Listy 2007; 101, 989-993.
  56. Kim J., Kim H., Ju C. Micronization and characterization of drug substances by RESS with supercritical CO2. Korean J. Chem Eng. 2010; 27, 1139-1144. Go to original source...
  57. Sander J. R. G., Zeiger B. W., Suslick K. S. Sonocrystallization and sonofragmentation. Ultrason. Sonochem. 2014; 21, 1908-1915. Go to original source... Go to PubMed...
  58. Nireesha G., Divya L., Sowmya C., Venkateshan N., Babu M. N., Lavakumar V. Lyophilization/freeze drying - an review. International Journal of Novel Trends in Pharmaceutical Sciences 2013; 3, 87-98.
  59. Yasmin R., Tan A., Bremmell K. E., Prestidge C. A. Lyophilized silica lipid hybrid (SLH) carriers for poorly water-soluble drugs: physicochemical and in vitro pharmaceutical investigations. J. Pharm. Sci. 2014; 103, 2950-2959. Go to original source... Go to PubMed...
  60. Sahoo N. G., Abbas A., Judeh Z., Li C. M., Yuen K. H. Solubility enhancement of a poorly water-soluble anti-malarial drug: Experimental design and use of a modified multifluid nozzle pilot spray drier. J. Pharm. Sci. 2009; 98, 281-296. Go to original source... Go to PubMed...
  61. Sollohub K., Cal K. Spray drying technique: II. current applications in pharmaceutical technology. J. Pharm. Sci. 2010; 99, 587-597. Go to original source... Go to PubMed...
  62. Walters R. H., Bhatnagar B., Tchessalov S., Izutsu K., Tsumoto K., Ohtake S. Next generation drying technologies for pharmaceutical applications. J. Pharm. Sci. 2014; 103, 2673-2695. Go to original source... Go to PubMed...
  63. Vandana K. R., Raju Y. P., Chowdary V. H., Sushma M., Kumar V. N. An overview on in situ micronization technique - an emerging novel concept in advanced drug delivery. Saudi Pharm. J. 2014; 22, 283-289. Go to original source... Go to PubMed...
  64. Joshi J. T. A review on micronization techniques. Journal of Pharmaceutical Science and Technology 2011; 3, 651-681.
  65. Bansal K., Pant P., Rao P. R. T., Padhee K, Sathapathy A., Kochhar P. S. Micronization and dissolution enhancement of norethindrone. International Journal of Research in Pharmacy and Chemistry 2011; 1, 315-319.
  66. Chen H., Khemtong C., Yang X., Chang X., Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov. Today 2011; 16, 354-360. Go to original source... Go to PubMed...
  67. Balakrishnan A., Rege B. D., Amidon G. L., Polli E. Surfactant-mediated dissolution: Contributions of solubility enhancement and relatively low micelle diffusivity. J. Pharm. Sci. 2004; 93, 2064-2075. Go to original source... Go to PubMed...
  68. Bajaj H., Bisht S., Yadav M., Singh V. Bioavaolability enhancement: a review. International Journal of Pharma and Bio Sciences 2011; 2, 202-216.
  69. Sikarra D., Shukla V., Kharia A. A., Chatterjee D. P. Techniques for solubility enhancement of poorly soluble drugs: an overview. Journal of Medical Pharmaceutical and Allied Sciences 2012; 1, 1-22. Go to original source...
  70. Li P., Yhao L. Solubilization of flurbiprofen in pH-surfactant solutions. J. Pharm. Sci. 2003; 92, 951-956. Go to original source... Go to PubMed...
  71. Rangel-Yagui C. O., Pessoa Jr. A., Taveres L. C. Micellar solubilization of drugs. J. Pharm. Pharm. Sci. 2005; 8, 147-163.
  72. Zhu J., Bierwagen G. P. The surface chemistry of water-reducible polymer solutions/dispersions - 1. Surface tension behavior. Prog. Org. Coat. 1995; 26, 87-100. Go to original source...
  73. Kawakami K., Oda N., Miyoshi K., Funaki T., Ida Y. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents. Eur. J. Pharm. Sci. 2006; 28, 7-14. Go to original source... Go to PubMed...
  74. Vemula V. R., Lagishetty V., Lingala S. Solubility enhancement techniques. International Journal of Pharmaceutical Sciences Review and Research 2010; 5, 41-51. Go to original source...
  75. Jangher A., Griffiths P. C., Paul A., King S. M., Heenan R. K., Schweins R. Polymeric micelle disruption by cosolvents and anionic surfactants. Colloid and Surface A. 2011; 391, 88-94. Go to original source...
  76. Patil A. E., Devtalu S. V., Bari M. M., Barthel S. D. A review on: novel solubility enhancement technique hydrotropy. Indo American Journal of Pharmaceutical Research 2013; 3, 4670-4679.
  77. Kumar V. S., Raja C., Jayakumar C. A review on solubility enhancement using hydrotropic phenomena. International Journal of Pharmacy and Pharmaceutical Sciences 2014; 6, 1-7.
  78. Terao K., Nakata D., Fukumi H., Schmid G., Arima H., Hirayama F., Uekama K. Enhancement of oral bioavailability of coenzyme Q10 by complexation with γγ-cyclodextrin in healthy adults. Nutr. Res. 2006; 26, 503-508. Go to original source...
  79. Dvořáčková K. Principy uvolňování léčiv z perorálních matricových tablet obsahujících hypromelosu. Chem. Listy 2009; 103, 66-72.
  80. Okáčová L., Vetchý D., Franc A, Rabišková M. Zvýšení biodostupnosti těžce rozpustných léčivých látek technologickými postupy usnadňujícími jejich rozpouštění. Chem. Listy 2011; 105, 34-40.
  81. Sinha S., Ali, M., Baboota S., Ahuja A., Kumar A., Ali J. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech. 2010; 11, 518-527. Go to original source... Go to PubMed...
  82. Baek H. H., Kim D. H., Kwon S. Y., Rho S. J., Kim D. W., Choi H. G., Kim Y. R., Yong C. S. Development of novel ibuprofen-loaded solid dispersion with enhanced bioavailability using cycloamylose. Arch. Pharm. Res. 2012; 35, 683-689. Go to original source... Go to PubMed...
  83. Zatloukal Z. Interaktivní práškové směsi. Čes. slov. Farm. 2004; 53, 165-171.
  84. Allahham A., Stewart P. J. Enhancement of the dissolution of indomethacin in interactive mixtures using added fine lactose. Eur. J. Pharm. Biopharm. 2007; 67, 732-742. Go to original source... Go to PubMed...
  85. Watano S., Imada Y., Hamada K., Wakamatsu Y., Tanabe Y., Dave R. N., Pfeffer R. Microgranulation of fine powders by a novel rotating fluidized bed granulation. Powder Technol. 2003; 131, 250-255. Go to original source...
  86. Planinšek O., Kovačič B., Vrečer F. Carvediol dissolution improvement by preparation of solid dispersions with porous silica. Int. J. Pharm. 2011; 406, 41-48. Go to original source... Go to PubMed...
  87. Krupa A., Jachowicz R., Kurek M., Figiel W., Kwiecień M. Preparation of solid self-emulsifying drug delivery systems using magnesium aluminometasilicates and fluid-bed coating proces. Powder Technol. 2014; 266, 329-339. Go to original source...
  88. Yang H., Teng F., Wang P., Tian B., Lin X., Hu X., Zhang L., Zhang K., Zhang Y., Tang Y. Investigation of a nanosuspension stabilized by Soluplus® to improve bioavailability. Int. J. Pharm. 2014; 477, 88-95. Go to original source... Go to PubMed...
  89. Kulkarni S. A., Aloorkar N. H., Mane M. S. Liquisolid systems: a review. International Journal of Pharmaceutical Sciences and Nanotechnology 2010; 3, 795- 802. Go to original source...
  90. Kavitha K., Lova Raju K. N. S., Ganesh N. S., Ramesh B. Effect of dissolution rate by liquisolid compacts approach: an overview. Der Pharmacia Lettre 2011; 3, 71-83.
  91. Shaikh J., Ankola D. D., Beniwal V., Singh D., Kumer M. N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J Pharm. Sci. 2009; 37, 223-230. Go to original source... Go to PubMed...
  92. Chen Y., Lu Y., Chen J., Lai J., Sun J., Hu F., Wu W. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int. J. Pharm. 2009; 376, 153-160. Go to original source... Go to PubMed...
  93. Petersen S. B., Nolan G., Maher S., Rahbek U. L., Gultdbrandt M., Brayden D. J. Evaluation of alkylmaltosides as intestinal permeation enhancers: comparison between rat intestinal mucosal sheets and Caco-2 monolayers. Eur. J. Pharm. 2012; 47, 801-712. Go to original source... Go to PubMed...
  94. Thanou M., Verhoef J. C., Junginger H. E. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev. 2001; 50, S91-101. Go to original source... Go to PubMed...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.